Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
This grant funds projects to improve effectiveness of mammalian models in cancer research for better clinical outcomes.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $499,000 direct costs per year, for a maximum project period of 5 years (R01 mechanism).
Summary: Supports projects to expand, improve, or transform the use of mammalian cancer and tumor models for translational research, with the goal of enhancing their clinical relevance and impact.
Key Information: Clinical trials are not allowed; foreign and domestic organizations are eligible; Data Management and Sharing Plan required.
Description
This opportunity, issued by the National Cancer Institute (NCI) at NIH, funds research projects aimed at enhancing the applicability of mammalian models (including organoids, tumoroids, and cell models) for translational cancer research. The focus is on demonstrating that these models robustly represent human biology, are suitable for addressing clinically relevant questions, and can reliably inform patient care. Projects may address technical, experimental, or practical challenges in the translational use of mammalian models, propose new uses or validation strategies, or develop best practices and standards for model use in translational settings.
Mechanistic, non-clinical research or the development of new models solely for non-clinical purposes is not responsive to this opportunity.
